The pharmaceutical company PSK Pharma has received a marketing authorization for its new drug, Ranibizumab PSK, intended for the treatment of severe retinal diseases.
The active substance, ranibizumab, is a monoclonal antibody that selectively blocks the pathological vascular growth factor and reduces edema, helping to preserve and improve patients’ vision.
The drug is used in the therapy of serious ophthalmic conditions such as neovascular age-related macular degeneration and proliferative diabetic retinopathy — a severe complication of diabetes that leads to decreased visual acuity.
Intravitreal administration of the drug delivers the active substance directly to the site of damage, ensuring high efficacy with minimal systemic side effects.
The demand for drugs containing this active substance is high in Russia due to the prevalence of these diseases. Since the beginning of the year, more than 30,000 packages of ranibizumab-containing medicines have been purchased through public procurement programs to provide patients with subsidized treatment.
The release of the domestically produced Ranibizumab PSK will ensure greater access to modern therapies for patients.
“Ranibizumab is another addition to our portfolio of high-tech biological medicines,” said Evgenia Shapiro, CEO of PSK Pharma. “We are offering therapies that meet the highest standards of quality and efficacy.”
The drug will be manufactured at PSK Pharma’s full-cycle production facility located in the Dubna Special Economic Zone, Moscow Region.
The product has been included in the list of Essential Medicines (EML).